In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
|Articles|September 17, 2020
Supplements and Featured Publications
- Long-Term Outcomes With Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
Long-Term Outcomes With Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
Advertisement
This publication was sponsored by CSL Behring.
This article presents the results of an open-label extension of the COMPACT trial, wherein the long-term safety and efficacy of 40- and 60-IU/kg C1-INH(SC) were assessed, were reported in a 2019 publication by Craig et al. Only the 60 IU/kg dose of HAEGARDA is approved for use.
Advertisement
Related to this article
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
A survivor shares axi-cel therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improves QOL.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Advertisement
Advertisement